Xeris Biopharma (XERS) CLO Beth Hecht reports grants, tax withholdings and share sale

Rhea-AI Filing Summary

Xeris Biopharma Holdings’ Chief Legal Officer and Corporate Secretary Beth Hecht reported multiple equity transactions in XERS stock. On January 30, 2026, she received 121,293 shares of common stock via restricted stock units and a grant of 162,162 stock options under the company’s 2018 Stock Option and Incentive Plan, both vesting in equal annual installments over three years.

On January 31, 2026, a total of shares were withheld at $7.36 per share to cover taxes on vested restricted stock units. On February 2, 2026, she sold 16,667 shares of common stock at a weighted average price of $7.4487 per share pursuant to a pre-arranged Rule 10b5-1 trading plan, leaving her with 1,243,174 shares of directly owned common stock.

Insider Trade Summary

Net Seller: 16,667 shares ($124,147)

Net Sell 6 txns

Insider Hecht Beth

Role See Remarks

Sold 16,667 shs ($124K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,667	$7.4487	$124K
Tax Withholding	Common Stock	98,375	$7.36	$724K
Tax Withholding	Common Stock	46,914	$7.36	$345K
Tax Withholding	Common Stock	24,266	$7.36	$179K
Grant/Award	Stock Option (Right to Buy)	162,162	$0.00	--
Grant/Award	Common Stock	121,293	$0.00	--

Holdings After Transaction: Common Stock — 1,243,174 shares (Direct); Stock Option (Right to Buy) — 162,162 shares (Direct)

Footnotes (1)

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		121,293(1)	A	$0	1,429,396	D
Common Stock	01/31/2026		F		98,375(2)	D	$7.36	1,331,021	D
Common Stock	01/31/2026		F		46,914(2)	D	$7.36	1,284,107	D
Common Stock	01/31/2026		F		24,266(2)	D	$7.36	1,259,841	D
Common Stock	02/02/2026		S(3)		16,667	D	$7.4487(4)	1,243,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.36	01/30/2026		A		162,162		(5)	01/30/2036	Common Stock	162,162	$0	162,162	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

2. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.

3. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Beth Hecht report in Xeris Biopharma (XERS)?

Beth Hecht reported receiving restricted stock units and stock options, tax-related share withholdings, and an open-market sale. The filing details grants on January 30, 2026, tax withholding transactions on January 31, 2026, and a Rule 10b5-1 plan sale of 16,667 XERS shares on February 2, 2026.

How many Xeris Biopharma (XERS) shares did Beth Hecht sell and at what price?

Beth Hecht sold 16,667 shares of Xeris Biopharma common stock. The weighted average sale price was $7.4487 per share, with individual trades executed between $7.250 and $7.590. The sale was carried out under a pre-established Rule 10b5-1 trading plan.

What equity awards did Beth Hecht receive from Xeris Biopharma (XERS)?

On January 30, 2026, Beth Hecht received 121,293 shares via restricted stock units and 162,162 stock options. Both awards were granted under Xeris Biopharma’s 2018 Stock Option and Incentive Plan and are scheduled to vest in equal annual installments over three years, subject to continued service.

Why were Xeris Biopharma (XERS) shares withheld from Beth Hecht’s awards?

Shares were withheld to satisfy income tax and withholding obligations. On January 31, 2026, Xeris Biopharma retained shares from vested restricted stock units at $7.36 per share, covering tax and remittance requirements tied to the net settlement of those equity awards.

How many Xeris Biopharma (XERS) shares does Beth Hecht own after these transactions?

After the reported transactions, Beth Hecht directly owns 1,243,174 shares of Xeris Biopharma common stock. This figure reflects the equity awards received, shares withheld for taxes, and the Rule 10b5-1 plan sale of 16,667 shares completed on February 2, 2026.

What are the vesting terms of Beth Hecht’s Xeris Biopharma (XERS) RSUs and options?

Both the restricted stock units and the stock options vest in equal annual installments over three years. Vesting is conditioned on Beth Hecht’s continued employment or service with Xeris Biopharma through each applicable vesting date, as specified under the company’s 2018 equity plan.